Exelon® Granted EU Marketing Authorization As First Treatment For Dementia Associated With Parkinson's Disease By European Commission

Novartis announced today that Exelon® (rivastigmine tartrate) has been granted European marketing authorization by the European Commission for the symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease (PD) in all 25 European member states.

Source: Medical News Today